• M344 Histone Deacetylase Inhibitor: Advanced Cancer Research

  2026-07-04

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor, enabling precise epigenetic modulation in neuroblastoma, breast cancer, and HIV latency models. This article details robust workflow enhancements, troubleshooting guidance, and practical protocol parameters that leverage M344’s unique profile for translational research breakthroughs.

• Rotigotine: Dopamine D2/D3 Receptor Agonist in PD Research

  2026-07-03

  Rotigotine stands out as a full dopamine D2/D3 receptor agonist, offering neuroprotection and robust symptom modulation in both in vitro and in vivo Parkinson's disease models. Cutting-edge workflows, such as nanoparticle nose-to-brain delivery, now enable enhanced neuronal targeting and bioavailability, revealing new opportunities for translational breakthroughs.

• Multiomics Profiling Reveals Mechanisms in Acute Liver Injur

  2026-07-03

  This study introduces a multiomics approach to dissect the therapeutic effects of bifendate and muaddil sapra in acute liver injury models. By integrating transcriptomic and proteomic analyses, the research uncovers key regulatory modules and molecular targets, offering new directions for intervention in liver damage.

• Tetrahydromagnolol: Advanced Peripheral CB2 Receptor Agonist

  2026-07-02

  Tetrahydromagnolol offers researchers a powerful, selective tool to dissect peripheral CB2 signaling in anti-inflammatory and metastasis models. Its superior potency and dual receptor activity enable precise modulation of GPCR pathways where conventional CB2 agonists fall short.

• L. acidophilus and UDCA Modulate Immunity in Ulcerative Coli

  2026-07-02

  This study uncovers how Lactobacillus acidophilus (LA) and its metabolite ursodeoxycholic acid (UDCA) ameliorate ulcerative colitis by promoting Treg differentiation and suppressing M1 macrophage polarization. The results reveal that LA’s therapeutic efficacy depends on gut microbiota and that UDCA mediates dual immunoregulatory actions via the RapGap/PI3K-AKT/NF-κB pathway, suggesting new avenues for microbiota-driven interventions in intestinal inflammation.

• Sulfo-NHS-SS-Biotin: Technical Guide for Cleavable Biotinyla

  2026-07-01

  Sulfo-NHS-SS-Biotin enables selective, reversible labeling of proteins and cell surface amines for affinity purification workflows. It is best suited for applications where efficient biotin tagging and subsequent label removal are required, but is not appropriate for intracellular or long-term labeling due to its membrane-impermeable and hydrolysis-prone chemistry.

• Continuous Dopaminergic Delivery with Rotigotine in PD and R

  2026-07-01

  This review details the development and clinical evaluation of the rotigotine transdermal system, which enables continuous dopaminergic stimulation for Parkinson’s disease (PD) and restless legs syndrome (RLS). The key innovation lies in overcoming oral delivery limitations by providing sustained, stable plasma concentrations, improving both motor and non-motor symptoms in PD and addressing moderate-to-severe RLS.

• Epinephrine Bitartrate: Precision Tools for Adrenergic Signa

  2026-06-30

  Epinephrine Bitartrate (SKU B1358) empowers researchers to dissect adrenergic signaling with reproducible precision, supporting both in vitro and in vivo workflows. This guide delivers actionable protocol enhancements and troubleshooting tips, drawing on recent clinical and bench science to ensure reliability from cell models to translational studies.

• Redefining mRNA Delivery: Strategic Innovation with EZ Cap™

  2026-06-30

  This thought-leadership article explores the mechanistic and strategic frontiers of enhanced mRNA delivery for translational research, blending recent advances in lipid nanoparticle formulation, immune evasion, and high-fidelity gene expression. Focusing on the synergistic features of EZ Cap™ EGFP mRNA (5-moUTP), it provides actionable guidance for optimizing reporter assays, translation efficiency, and in vivo imaging, while contextualizing these advances within the rapidly evolving landscape of machine learning-assisted carrier design and microglial immunomodulation.

• EPZ5676 (SKU A4166): Reliable DOT1L Inhibitor for Lab Precis

  2026-06-29

  EPZ5676 (SKU A4166) is a potent and highly selective DOT1L inhibitor, engineered for rigorous cell viability, proliferation, and cytotoxicity assays in leukemia and myeloma research. This article presents scenario-driven analysis for experimental design, data interpretation, and product selection, grounding recommendations in reproducible performance and validated protocols. Learn how leveraging EPZ5676 can optimize H3K79 methylation inhibition and support translational epigenetics.

• Carboplatin: Platinum-Based DNA Synthesis Inhibitor Benchmar

  2026-06-29

  Carboplatin is a platinum-based DNA synthesis inhibitor with well-characterized antiproliferative activity in preclinical oncology research. Recent studies clarify its mechanism of action and resistance pathways, particularly in ovarian and triple-negative breast cancer models, supporting optimized use in translational workflows.

• α-Amanitin in Transcriptional Regulation: Advanced Workflows

  2026-06-28

  α-Amanitin’s unparalleled selectivity for RNA polymerase II makes it the gold standard for dissecting gene expression and chromatin reorganization, especially in sensitive developmental models. This guide delivers actionable protocol design, troubleshooting, and comparative insights that empower researchers to maximize reproducibility and interpretive clarity using APExBIO’s α-Amanitin.

• Puerarin Enhances Osteogenic Differentiation via Nitric Oxid

  2026-06-27

  This study demonstrates that puerarin promotes the osteogenic differentiation of rat dental follicle cells (rDFCs) by activating the nitric oxide (NO) pathway. The findings clarify a mechanistic link between puerarin, NO signaling, and cellular markers of bone formation, offering evidence-based directions for periodontal regeneration strategies.

• Perphenazine: Bridging Dopaminergic and Immune Pathways in T

  2026-06-26

  Perphenazine, a dopamine D2 receptor antagonist, is redefining the boundaries of translational research by uniting neuropharmacology and host-directed immunomodulation. This article examines the mechanistic underpinnings, experimental validation, and strategic opportunities for researchers, moving beyond standard applications in schizophrenia and psychosis to spotlight Perphenazine’s versatile role in mitochondria-mediated cell death and antibacterial immune enhancement. Grounded in recent open-access evidence and positioned against the competitive landscape, we offer actionable guidance for advancing robust, cross-domain research workflows.

• Analytical Advances for Rotigotine: Impurity Control in PD R

  2026-06-26

  This review systematically examines analytical methodologies for assessing rotigotine and its impurities in raw materials and transdermal formulations. By comparing official pharmacopoeial standards and recent literature, the study clarifies quality control challenges vital for safe and effective Parkinson’s disease research and pharmaceutical development.

445 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page